Geneva Capital Management Portfolio holdings
Top Buys
| 1 |
Repligen
RGEN
|
+$43.8M |
| 2 |
Vertex
VERX
|
+$37.1M |
| 3 |
Valvoline
VVV
|
+$24.3M |
| 4 |
MACOM Technology Solutions
MTSI
|
+$20.1M |
| 5 |
Vericel Corp
VCEL
|
+$17.4M |
Top Sells
| 1 |
Kinsale Capital Group
KNSL
|
+$30.1M |
| 2 |
Construction Partners
ROAD
|
+$27.5M |
| 3 |
NVEE
NV5 Global
NVEE
|
+$17.7M |
| 4 |
Neogen
NEOG
|
+$17.4M |
| 5 |
DoubleVerify
DV
|
+$12.3M |
Sector Composition
| 1 | Technology | 34.2% |
| 2 | Industrials | 27.7% |
| 3 | Healthcare | 12.74% |
| 4 | Consumer Discretionary | 9.09% |
| 5 | Financials | 6.43% |
Similar funds
Geneva Capital Management's Q2 2025 Portfolio in Review
As of Q2 2025, Geneva Capital Management held 127 positions worth $5.97B, up 12% from $5.35B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Geneva Capital Management deployed $349M of net new capital in Q2 2025, opening 2 new positions and adding to 97 existing holdings. Its largest new stake was MACOM Technology Solutions: 172,230 shares worth $24.7M.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 33% a quarter earlier, followed by Industrials and Healthcare.
On the sell side, the largest reduction was Kinsale Capital Group, an estimated $30.1M trimmed.
- Geneva Capital Management's largest Q2 2025 buy was MACOM Technology Solutions: 172,230 shares worth $24.7M.
- Geneva Capital Management added most to Repligen in Q2 2025, an estimated $43.8M increase.
- Geneva Capital Management's biggest Q2 2025 reduction was Kinsale Capital Group, cutting an estimated $30.1M.
- Geneva Capital Management fully exited Neogen in Q2 2025, selling an estimated $17.4M.
- Geneva Capital Management's ten largest holdings make up 30% of its $5.97B portfolio in Q2 2025.
- Geneva Capital Management opened 2 new positions and closed 4 in Q2 2025.
- Geneva Capital Management's portfolio value rose 12% quarter-over-quarter to $5.97B.
Based on Geneva Capital Management's 13F filing for Q2 2025, filed 5 Aug 2025.